All Photos(1)

Key Documents

View All Documentation

EHU018261

MISSION^® esiRNA

Name: MISSION<SUP>®</SUP> esiRNA
Brand: SIGMA

targeting human ACY3

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

UNSPSC Code:

41105324

NACRES:

NA.51

Pricing and availability is not currently available.

description

Quality Level

100

product line

MISSION^®

form

lyophilized powder

esiRNA cDNA target sequence

CTTTGTCCTTGACCTGCACAACACCACGGCCAACATGGGCACCTGCTTAATCGCGAAGTCCTCCCACGAAGTCTTTGCCATGCACCTGTGCCGCCATCTGCAGCTGCAGTACCCCGAGCTGTCCTGCCAGGTCTTCCTGTACCAGCGGTCTGGGGAGGAGAGCTACAACCTGGACTCTGTGGCCAAAAATGGACTGGGTCTGGAGCTGGGCCCCCAGCCACAGGGTGTGCTGCGGGCTGACATTTTCTCAAGGATGAGGACCCTGGTGGCCACAGTTCTGGACTTCATCGAACTCTTCAACCAGGGTACGGCCTTTCCTGCCTTTGAGATGGAAGCCTATAGACCCGTGGGCGTCGTGGACTTCCCCCGCACCGAGGCCGGGCACCTGGCAGGCACTGTGCATCCTCAGCTGCAGGACCGAGACTTCCAGCCACTGCAGCCTGGTGCTCCCATCTTCCAGATGTTCAGTGGGGAGGACCTGCTCTATGAGGGAGAGTCCACGG

Ensembl | human accession no.

ENSG00000132744

NCBI accession no.

NM_080658

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... ACY3(91703), ACY3(91703)

Related Categories

MISSION® esiRNA

Oligos, qPCR Probes & Peptides

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	EHU018411	EHU021631	EHU050471
EHU018261 MISSION^® esiRNA	EHU018411 MISSION^® esiRNA	EHU021631 MISSION^® esiRNA	EHU050471 MISSION^® esiRNA
Ensembl \| human accession no. ENSG00000132744	Ensembl \| human accession no. ENSG00000138031	Ensembl \| human accession no. ENSG00000101342	Ensembl \| human accession no. ENSG00000007202
Gene Information human ... ACY3(91703), ACY3(91703)	Gene Information human ... ADCY3(109), ADCY3(109)	Gene Information human ... TLDC2(140711), C20orf118(140711)	Gene Information human ... KIAA0100(9703), KIAA0100(9703)
product line MISSION^®	product line MISSION^®	product line MISSION^®	product line MISSION^®
esiRNA cDNA target sequence CTTTGTCCTTGACCTGCACAACACCACGGCCAACATGGGCACCTGCTTAATCGCGAAGTCCTCCCACGAAGTCTTTGCCATGCACCTGTGCCGCCATCTGCAGCTGCAGTACCCCGAGCTGTCCTGCCAGGTCTTCCTGTACCAGCGGTCTGGGGAGGAGAGCTACAACCTGGACTCTGTGGCCAAAAATGGACTGGGTCTGGAGCTGGGCCCCCAGCCACAGGGTGTGCTGCGGGCTGACATTTTCTCAAGGATGAGGACCCTGGTGGCCACAGTTCTGGACTTCATCGAACTCTTCAACCAGGGTACGGCCTTTCCTGCCTTTGAGATGGAAGCCTATAGACCCGTGGGCGTCGTGGACTTCCCCCGCACCGAGGCCGGGCACCTGGCAGGCACTGTGCATCCTCAGCTGCAGGACCGAGACTTCCAGCCACTGCAGCCTGGTGCTCCCATCTTCCAGATGTTCAGTGGGGAGGACCTGCTCTATGAGGGAGAGTCCACGG	esiRNA cDNA target sequence GGCCTTAGAGCAGATGCAAGGATTCAACCCTGGGCTCAATGGCACTGACAGGCTGCCCCTGGTGCCTTCCAAGTACTCTATGACGGTGATGGTGTTCCTCATGATGCTCAGCTTCTACTACTTCTCCCGCCACGTAGAAAAACTGGCACGGACACTTTTCTTGTGGAAGATTGAGGTCCACGACCAGAAGGAACGTGTCTATGAGATGCGACGCTGGAACGAGGCCTTGGTCACCAACATGTTGCCTGAGCACGTGGCACGCCATTTCCTGGGGTCCAAGAAGAGAGATGAGGAGCTGTATAGCCAGACGTATGATGAGATTGGAGTCATGTTTGCCTCCCTGCCCAACTTTGCTGACTTCTACACAGAGGAGAGCATCAACAATGGTGGTATTGAGTGTCTGCGTTTCCTCAATGAAATCATCTCAGATTTTGACTCTCTCCTGGACAATCCCAAGTTCCGGGTGATCACCAAGATCAAAACCATTGGCAGCACGTATATGG	esiRNA cDNA target sequence GCTATCCGACTCAGCAAAGGCTTCTATGGTACTGGCGAGACATTCCTCTTCTCCTTCTCCCCACAGCTGAAGGTCTTTAAGTGGACTGGAAGCAACTCTTTCTTTGTGAAGGGAGACTTGGATTCACTGATGATGGGCAGTGGCAGTGGCCGGTTTGGGCTGTGGTTGGATGGAGACTTGTTCCGCGGGGGAAGCTCCCCTTGCCCGACCTTCAACAACGAGGTGCTGGCCCGGCAGGAGCAGTTCTGCATCCAGGAGCTGGAGGCTTGGCTTCTCAGCTGACAGCCCTGCGGCAACAGAATTCTATGATTGAAGCCTCTAAATGAATTGTGCAGGAGAGGGAGTTTGTAAACAACTGACTACAGACATTCACATTGGGTCATCTTTAAAAAGCTGGACTCTGCTTTTGGATGCTTCTCGGAG	esiRNA cDNA target sequence CCACCAACCCAGCTCAGTATGCCATGATCCTGGACATTGTCAACAACCTGCTGCTCCATGTAGAACCTAAGCGGAAGGAACATAGTGAGAAGAAGCAACGGGTCAGGTTCCAGCTTGAGATCTCTAGCAATCCAGAGGAGCAACGCAGCAGCATACTGCATTTGCAGGAGGCTGTGCGGCAGCATGTGGCCCAAATACGACAGCTGGAGAAGCAGATGTATTCTATCATGAAGTCTTTGCAGGATGACAGCAAGAATGAGAATCTGCTTGACCTGAACCAGAAGCTTCAGTTGCAGCTAAACCAGGAGAAGGCCAACCTGCAGCTGGAAAGTGAAGAACTGAATATCCTCATCAGGTGTTTTAAGGATTTCCAACTGCAGCGGGCTAACAAGATGGAGCTGC
form lyophilized powder	form lyophilized powder	form lyophilized powder	form lyophilized powder
NCBI accession no. NM_080658	NCBI accession no. NM_004036	NCBI accession no. NM_080628	NCBI accession no. NM_014680

General description

MISSION^® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Inhibition of Voltage-Gated K+ Channel Kv1.5 by Antiarrhythmic Drugs.

Rong Chen et al.

Biochemistry, 57(18), 2704-2710 (2018-04-14)

Molecular dynamics simulations are employed to determine the inhibitory mechanisms of three drugs, 5-(4-phenoxybutoxy)psoralen (PAP-1), vernakalant, and flecainide, on the voltage-gated K+ channel Kv1.5, a target for the treatment of cardiac arrhythmia. At neutral pH, PAP-1 is neutral, whereas the

Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca2+-Activated K+ Channels in Pigs.

Jonas Goldin Diness et al.

Circulation. Arrhythmia and electrophysiology, 10(10) (2017-10-12)

Evidence has emerged that small-conductance Ca2+-activated K+ (SK) channels constitute a new target for treatment of atrial fibrillation (AF). SK channels are predominantly expressed in the atria as compared with the ventricles. Various marketed antiarrhythmic drugs are limited by ventricular

Antiarrhythmic effect of vernakalant in an experimental model of Long-QT-syndrome.

Gerrit Frommeyer et al.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 19(5), 866-873 (2016-10-06)

The antiarrhythmic drug vernakalant exerts antiarrhythmic effects in atrial fibrillation. Recent experimental data suggest interactions with the late sodium current and antiarrhythmic effects in ventricular arrhythmias. We aimed at investigating whether treatment with vernakalant reduces polymorphic ventricular tachycardia (VT) in

Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits.

Toshiki Chiba et al.

Journal of pharmacological sciences, 130(3), 170-176 (2016-04-02)

Electrical remodeling plays a pivotal role in maintaining the reentry during atrial fibrillation. In this study, we assessed influence of electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits. We used an atrial electrical remodeling model of the

Comparison of vernakalant and ranolazine in atrial fibrillation.

Gerrit Frommeyer et al.

Journal of cardiovascular medicine (Hagerstown, Md.), 18(9), 663-668 (2017-07-12)

Current guidelines recommend vernakalant for pharmacologic cardioversion of recent-onset atrial fibrillation. However, this drug is not established as chronic therapy. In total, 15 rabbit hearts were Langendorff-perfused. A burst pacing protocol-induced atrial fibrillation in 7 of 15 hearts at baseline

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service